FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

asnington, L	.C. 20549		

OMB APPROVAL								
OMB Number:	3235-028							
Estimated average bi	urden							

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Geary Richard S</u>					2. Issuer Name and Ticker or Trading Symbol IONIS PHARMACEUTICALS INC [IONS]								eck all applic Directo	Officer (give title Other		10% Ow	Owner r (specify	
(Last) (First) (Middle) C/O IONIS PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 01/01/2018								below)	below)					
2855 GAZELLE COURT (Street) CARLSBAD CA 92010 (City) (State) (Zip)				4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(- 9)	(-			n-Deri	vativ	e Se	curities	s Ac	guired. I	Dis	posed of	f. or Ber	neficial	v Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			saction	2A. Deemed Execution Date,		3. 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		d (A) or	5. Amou Securitie Benefici	s Formally (D) of ollowing (I) (In		n: Direct I or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership					
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)			(Instr. 4)	
Common Stock 01/01/				1/201	/2018 01/01/2018		J ⁽¹⁾	v	320(1)	A	\$42.75	55 12	12,671		D			
			Table II -								osed of, onvertib			Owned				
Derivative Conversion D		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	ution Date, Tr		ection Instr.	of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	i lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				,	Code	v	(A)		Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to	\$49.25	01/02/2018	01/02/20)18	A		58,125		01/02/2019 ⁰	2)	01/02/2025	Common Stock	58,125	\$0	58,12	5	D	

Explanation of Responses:

- 1. Reporting 320 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 320 shares may not be sold until July 2, 2018.
- 2. Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 14,531 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.

Remarks:

/s/B. Lynne Parshall, attorney-

01/02/2018

<u>in-fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.